- Home
- DLB vs ROIV Comparison
DLB vs ROIV Comparison
Compare DLB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLB
- ROIV
- Stock Information
- Founded
- DLB 1965
- ROIV 2014
- Country
- DLB United States
- ROIV United Kingdom
- Employees
- DLB N/A
- ROIV N/A
- Industry
- DLB Multi-Sector Companies
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- DLB Miscellaneous
- ROIV Health Care
- Exchange
- DLB Nasdaq
- ROIV Nasdaq
- Market Cap
- DLB 7.9B
- ROIV 8.4B
- IPO Year
- DLB 2005
- ROIV N/A
- Fundamental
- Price
- DLB $75.74
- ROIV $10.91
- Analyst Decision
- DLB Strong Buy
- ROIV Buy
- Analyst Count
- DLB 4
- ROIV 4
- Target Price
- DLB $101.75
- ROIV $17.50
- AVG Volume (30 Days)
- DLB 384.8K
- ROIV 5.5M
- Earning Date
- DLB 05-01-2025
- ROIV 05-29-2025
- Dividend Yield
- DLB 1.74%
- ROIV N/A
- EPS Growth
- DLB 36.08
- ROIV N/A
- EPS
- DLB 2.64
- ROIV N/A
- Revenue
- DLB $1,320,184,000.00
- ROIV $122,585,000.00
- Revenue This Year
- DLB $6.38
- ROIV N/A
- Revenue Next Year
- DLB $4.65
- ROIV N/A
- P/E Ratio
- DLB $28.82
- ROIV N/A
- Revenue Growth
- DLB 4.03
- ROIV 140.04
- 52 Week Low
- DLB $66.35
- ROIV $8.73
- 52 Week High
- DLB $89.66
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- DLB 48.04
- ROIV 52.03
- Support Level
- DLB $76.69
- ROIV $10.58
- Resistance Level
- DLB $77.59
- ROIV $11.77
- Average True Range (ATR)
- DLB 1.26
- ROIV 0.33
- MACD
- DLB 0.20
- ROIV -0.04
- Stochastic Oscillator
- DLB 57.08
- ROIV 28.57
About DLB Dolby Laboratories
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.